Biopharm
Follow
Find
4.5K views | +0 today
 
Rescooped by H. Fai Poon from Tissue Engineering, cell culture
onto Biopharm
Scoop.it!

The keys to Stemless are in the media: Physical cues help mature cells revert into embryonic-like stem cells

The keys to Stemless are in the media: Physical cues help mature cells revert into embryonic-like stem cells | Biopharm | Scoop.it
Bioengineers have shown that physical cues can help reprogram mature cells back into pluripotent stem cells. The study demonstrates for the first time that biomaterials can help regulate the memory of a cell's identity.

Via Jacob Blumenthal, Valérie Cenizo
H. Fai Poon's insight:

Good read to update you stem cell knowledge.

more...
Jacob Blumenthal's curator insight, October 22, 2013 7:08 AM

In a paper, published in Nature Materials by Downing el al, the researchers demonstrate how surface microtopography enhance reprogramming of mature cells into induced pluripotent stem (iPS) cells. They found that parallel microgrooves,can replace the effects of small-molecule epigenetic modifiers and significantly improve reprogramming efficiency.

http://www.nature.com/nmat/journal/vaop/ncurrent/full/nmat3777.html

Biopharm
Your new post is loading...
Your new post is loading...
Scooped by H. Fai Poon
Scoop.it!

Amgen's PCSK9 outcomes trial to deliver data sooner than expected

Amgen's PCSK9 outcomes trial to deliver data sooner than expected | Biopharm | Scoop.it
The wait for outcomes data on Amgen's PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the second half of 2016.
H. Fai Poon's insight:
always a good sign when the study end early.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

!Think different? Pharma turns to tech partnerships for beyond-the-pill moves

!Think different? Pharma turns to tech partnerships for beyond-the-pill moves | Biopharm | Scoop.it
There's not going to be a beyond-the-pill revolution in 2016. Frankly, pharma doesn't yet have the technology to move beyond pushing products to delivering outcomes.
H. Fai Poon's insight:
this is a new change of pharma coming
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Theranos exemplifies clash of new versus old in-vitro test models - FT.com

Theranos exemplifies clash of new versus old in-vitro test models - FT.com | Biopharm | Scoop.it
If there is any part of the US healthcare market that is ripe for disruption, it is surely in-vitro diagnostics — medical examinations that take place outside the human body such as blood tests in a test tube or culture dish. Ask any American about
H. Fai Poon's insight:

I think this is just matter of time for the direct to patiet rout take over!

more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

U.K. cost watchdog gives one-two punch to Roche's Kadcyla and BMS' Opdivo

U.K. cost watchdog gives one-two punch to Roche's Kadcyla and BMS' Opdivo | Biopharm | Scoop.it
The U.K. cost gatekeeper National Institute for Health and Care Excellence (NICE) gave a one-two punch to Roche and Bristol-Myers Squibb's costly cancer drugs, rejecting Roche's breast cancer therapy Kadcyla and giving its thumbs-down to BMS' lung...
H. Fai Poon's insight:
nice is absolutely Right . thebkife extention is Less than 1 year
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Chinese advisers push for tougher generics quality standards

Chinese advisers push for tougher generics quality standards | Biopharm | Scoop.it
China's political advisers are encouraging domestic generic drug development--but at the same time, they're also pushing for tougher quality standards.
H. Fai Poon's insight:
I think tHe key is to develop a culture of excellence and pride of their work.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Johns Hopkins accuses drugmakers of 'gaming' orphan drug law

Johns Hopkins accuses drugmakers of 'gaming' orphan drug law | Biopharm | Scoop.it
The Orphan Drug Act has led to drugmakers developing treatments for very small populations of patients who before suffered or died from rare disease with no hope of a cure.
H. Fai Poon's insight:
I think the way to patch this is making the subsidy as installment. as soon as the Drug cover Another disease, subsidy should be gone.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Struggling Eisai looks for help in China with new generics deal

Struggling Eisai looks for help in China with new generics deal | Biopharm | Scoop.it
Eisai's had a rough few years, but it's predicted an upswing in operating profit in the not-too-distant future. And to help it get there, it's struck a new deal in China.
H. Fai Poon's insight:
China is destine to be no.1 pharma market. I think now is time to pour money in.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti

Bristol-Myers puts a blockbuster $142K price on new cancer med Empliciti | Biopharm | Scoop.it
After winning FDA approval Monday, the latest multiple myeloma treatment--Empliciti, from Bristol-Myers Squibb and AbbVie--is about to hit the scene. And like its rivals in the field, it'll be pricey.
H. Fai Poon's insight:
So many cancer drug
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

FDA approves BMS' Opdivo for kidney cancer a week after granting priority review

FDA approves BMS' Opdivo for kidney cancer a week after granting priority review | Biopharm | Scoop.it
In another striking FDA turnaround for Bristol-Myers Squibb's Opdivo, the agency has approved it for treating advanced renal cell carcinoma just a week after granting priority review.
H. Fai Poon's insight:
Another approval in the bag. Pd1 Sounds Like a magic drug.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Dr. Reddy's strikes back at AstraZeneca in purple pill courtroom battle

Dr. Reddy's strikes back at AstraZeneca in purple pill courtroom battle | Biopharm | Scoop.it
AstraZeneca has been duking it out with Dr. Reddy's Laboratories over generic Nexium, winning a round last week after a Delaware district judge put the kibosh on sales of Dr.
H. Fai Poon's insight:
The color of a pill will cost law suit?
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Shortages, soaring generic injectable drug prices leave hospitals scrambling

Shortages, soaring generic injectable drug prices leave hospitals scrambling | Biopharm | Scoop.it
Hospital pharmacy folk understand supply and demand and realize that when there is a shortage of the generic injectables drugs they routinely use, a big price hike is coming.
H. Fai Poon's insight:
my solution is to start an option contract for drug. And Also looking for a Better alternative.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering

Catalent stops production at French plant, brings in law enforcement after it twice detects tampering | Biopharm | Scoop.it
U.S.-based Catalent has halted production at a drug manufacturing facility in France at the request of regulators after several incidents in which it appears someone within the plant purposely mixed the wrong capsules into batches.
H. Fai Poon's insight:
I cannot understand why people would do things like that?
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

China's new pharma crackdown may help top companies

China's new pharma crackdown may help top companies | Biopharm | Scoop.it
​China's Food and Drug Administration is cracking down on drugmakers, rejecting 11 applications for generic treatments in a move widely seen as an effort to bolster confidence in the country's biopharma industry by demanding that players meet...
H. Fai Poon's insight:
I think this is a very smart move. Only way to go is to ensure quality.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

The biosimilars are coming. But how long will it be till they can make their mark?

The biosimilars are coming. But how long will it be till they can make their mark? | Biopharm | Scoop.it
With one biosim already on the U.S. market, and more poised for a 2016 liftoff, next year will give drugmakers and payers a taste of the biosim contest to come.
H. Fai Poon's insight:
the price of biosimilar are a lot less than expected mostly due to regulatory and technical improvement.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Brace yourselves: The drug pricing brouhaha isn't dying down

Brace yourselves: The drug pricing brouhaha isn't dying down | Biopharm | Scoop.it
Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price of a 62-year-old drug by 5,000%-plus--to $750 per pill from $13.50.
H. Fai Poon's insight:
drugs are inelastic goods. so they dont lost customer when their price go up. the pharma have to take social responsibility above profit.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Valeant's big pharmacy deal with Walgreens includes quirky drug-buyback plan

Valeant's big pharmacy deal with Walgreens includes quirky drug-buyback plan | Biopharm | Scoop.it
Valeant Pharmaceuticals' much-ballyhooed agreement with Walgreens includes an unusual inventory provision that helps explain why the pharmacy chain might have been eager to strike a deal.
H. Fai Poon's insight:
less middle man is a better deal for patients
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Sanofi-Boehringer talks may signal more swaps ahead for 'merger mania' in 2016

Sanofi-Boehringer talks may signal more swaps ahead for 'merger mania' in 2016 | Biopharm | Scoop.it
Is the swap destined to be pharma's next M&A trend?
H. Fai Poon's insight:
this is a lesson from playing monopoly.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Lawmaker calls out Turing for 'Orwellian double-speak' on pricing

Lawmaker calls out Turing for 'Orwellian double-speak' on pricing | Biopharm | Scoop.it
Last week, Turing Pharmaceuticals revealed it would not lower the price of its toxoplasmosis drug, Daraprim, offering discounts to hospitals instead and planning to roll out smaller bottles with fewer tablets to defray costs.
H. Fai Poon's insight:
more regulation was never the answer. just let the market set the price. its an off patent drug and people can make generic if the price is right.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug

Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drug | Biopharm | Scoop.it
Japan is considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy.
H. Fai Poon's insight:
the price is reasonable.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Russia amps up spending on locally made meds to spur Big Pharma production

Russia amps up spending on locally made meds to spur Big Pharma production | Biopharm | Scoop.it
Russia has a lot of purchasing muscle, but few local producers when it comes to pharmaceuticals, and so officials have cooked up a plan to lure more foreign pharma partners.
H. Fai Poon's insight:
Go russia. This seems like a global trend.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA

Dr. Reddy's blasted in warning letter for hiding existence of testing lab from FDA | Biopharm | Scoop.it
An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to the U.S. products that had repeatedly failed tests for impurities.
H. Fai Poon's insight:
Uncontrol custom lab... wow... crazy
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Regeneron plots a $150M R&D expansion, adding 300 jobs at its New York hub

Regeneron plots a $150M R&D expansion, adding 300 jobs at its New York hub | Biopharm | Scoop.it
Regeneron Pharmaceuticals, riding high with a top-selling eye drug and some promising pipeline assets, is planning to invest $150 million in its native New York, supporting 300 new jobs at its fast-growing R&D campus.
H. Fai Poon's insight:
Regeneron pipeline. Full of autoimmue disease.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha

U.K. cost gatekeeper says 'no' to Amgen's PCSK9 cholesterol fighter Repatha | Biopharm | Scoop.it
Amgen got a thumbs-down from U.K. cost watchdog the National Institute for Health and Care Excellence (NICE) for its PCSK9 cholesterol-fighter Repatha (evolocumab), bad news for the drug as it contends with pricing pushback and competes...
H. Fai Poon's insight:
Pcsk9 is an over rated biologics. Not because of it efficacy, it is Because of the oral dosage alternatives.
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

AstraZeneca stokes Tagrisso's blockbuster hopes with $12,750-per-month sticker

AstraZeneca stokes Tagrisso's blockbuster hopes with $12,750-per-month sticker | Biopharm | Scoop.it
AstraZeneca unveiled its pricing plan for the new targeted lung cancer pill Tagrisso that won early FDA approval Friday: $12,750 per month, or $153,000 for a full year of treatment.
H. Fai Poon's insight:
New target alert. Mutated efgr
more...
No comment yet.
Scooped by H. Fai Poon
Scoop.it!

Mesoblast disappoints in another below-the-range biotech IPO

Mesoblast disappoints in another below-the-range biotech IPO | Biopharm | Scoop.it
Australian biotech Mesoblast priced its U.S. IPO below expectations, raising $60 million to support its pipeline of cell therapies.
H. Fai Poon's insight:
That will be 60 million for 5 candidate.
more...
No comment yet.